Cross-reactive carbohydrate determinant-specific immunoglobulin E (anti-CCD IgE)

Cross-reactive carbohydrate determinant-specific immunoglobulin E (anti-CCD IgE) is a class of antibodies that recognize N-linked glycans containing alpha-1,3-fucose or beta-1,2-xylose, which are common in plants and insects but absent in humans (Altmann, 2016). These antibodies are found in approximately 20-30% of allergic patients and are characterized by their broad cross-reactivity across diverse allergen sources, including pollen, latex, and Hymenoptera venom (Holzweber et al., 2013). Despite their high prevalence and ability to bind allergens in vitro, anti-CCD IgE antibodies are generally considered clinically irrelevant because they typically fail to cross-link FcεRI receptors effectively enough to trigger mast cell degranulation (Jappe et al., 2018). Their primary significance lies in the diagnostic field, where they cause false-positive results in specific IgE (sIgE) assays, complicating the identification of true clinical sensitivities. To mitigate this, diagnostic laboratories often use CCD blockers to neutralize these antibodies before testing (Jappe et al., 2018). While not a direct target for traditional pharmacotherapy, they are sequestered by anti-IgE biologics like omalizumab, which reduces the overall pool of circulating IgE (National Institutes of Health, 2023).

Other names

CCD-specific IgEAnti-CCD IgEIgE against plant N-glycansMUXF3-specific IgEAnti-glycan IgE

Omalizumab is a monoclonal antibody that binds to the Cε3 domain of circulating IgE, preventing its interaction with high-affinity IgE receptors (FcεRI) on mast cells and basophils (National Institutes of Health, 2023). Diagnostic CCD blockers are synthetic or purified glycopeptides that act as competitive inhibitors, saturating the carbohydrate-binding sites of anti-CCD IgE antibodies to prevent them from binding to CCD-containing allergens in diagnostic assays (Jappe et al., 2018).